Key Studies in Genitourinary, Gastrointestinal, Breast, and Lung Cancers: CCO Independent Conference Highlights of the 2021 Virtual ESMO Annual Meeting
  • CME

September 16-21, 2021; Virtual
Review expert perspectives on the most clinically relevant data on genitourinary, gastrointestinal, breast, and lung cancers presented at the 2021 virtual ESMO annual meeting.
Eva M. Ciruelos, MD, PhD
Karim Fizazi, MD, PhD
Eric Van Cutsem, MD, PhD
person default
Vamsidhar Velcheti, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: December 15, 2021 Expiration: December 14, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with cancer
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with cancer
  • Consider how new trial findings might affect treatment of cancer clinical practice in the future

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Eva M. Ciruelos, MD, PhD

Associate Professor
Medicine and Surgery
Complutense University
Medical Oncologist, Breast Cancer Coordinator
Medical Oncology Dpt, Hospital 12 de Octubre and HM Hospitales
Madrid, Spain

Eva M. Ciruelos, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca/Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche and fees for non-CME/CE services from AstraZeneca/Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Pfizer, and Roche.
Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Karim Fizazi, MD, PhD, has disclosed that he has received consulting fees from AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, CureVac, ESSA, Genentech, Janssen, Merck Sharp & Dohme, Orion, and Sanofi.
Eric Van Cutsem, MD, PhD

Professor of Medicine
University of Leuven
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

Eric Van Cutsem, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Array, Astellas, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GlaxoSmithKline, Helsinn, Incyte, Ipsen, Janssen Research, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Pierre Fabre, Roche, Seattle Genetics, Servier, Sirtex, Terumo, Taiho, TRIGR, and Zymeworks and funds for research support paid to his institution from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier.
Vamsidhar Velcheti, MD

Associate Professor, Thoracic Oncology
Director, Thoracic Oncology Program
Department of Medical Oncology
New York University
New York, New York

Vamsidhar Velcheti, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Foundation Medicine, Merck, and Novartis.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant conflicts of interest to report.
Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with cancer.

Goal

The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice-changing clinical data on the treatment of patients with cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2021, through December 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: May 17, 2022 Expired: May 16, 2023

Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 17, 2022

Module from Clinical Care Options (CCO): Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, discuss current treatment of cholangiocarcinoma, including the use of biomarkers

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings